SCHEMBL2953586

SCHEMBL2953586

CCCN(CC)C(=O)C1CC1

nearest known ligand 0.47

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.44
PKM P14618 2/20 0.44
BCHE P06276 2/20 0.43
L3MBTL1 Q9Y468 1/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
CA12 O43570 1/20 0.41
CA2 P00918 1/20 0.41
CA9 Q16790 1/20 0.41
KDM4E B2RXH2 2/20 0.40
TSHR P16473 1/20 0.39
MAPK1 P28482 1/20 0.39
SLC6A2 P23975 1/20 0.38
SLC6A4 P31645 1/20 0.38
CNR2 P34972 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17208375 0.94 ALDH1A1 (0.41) ALDH1A1PKMBCHEL3MBTL1MEN1
SCHEMBL17208378 0.94 ALDH1A1 (0.41) ALDH1A1PKMBCHEL3MBTL1MEN1
SCHEMBL2960396 0.91 BCHE (0.49) ALDH1A1PKMBCHEL3MBTL1MEN1
SCHEMBL21322829 0.90 CNR2 (0.47) ALDH1A1BCHEKDM4ECNR2
SCHEMBL20928014 0.88 BCHE (0.44) ALDH1A1PKMBCHEL3MBTL1MEN1
SCHEMBL1289738 0.86 ALDH1A1 (0.47) ALDH1A1PKMBCHEMEN1KMT2A
SCHEMBL21650158 0.86 CNR2 (0.50) ALDH1A1PKMBCHEL3MBTL1MEN1
SCHEMBL623223 0.85 ALDH1A1 (0.42) ALDH1A1PKMBCHEL3MBTL1MEN1
SCHEMBL2960994 0.84 CNR2 (0.52) BCHEL3MBTL1MEN1KMT2ACA12
Hydrochloric Acid SCHEMBL1289689 0.84 ALDH1A1 (0.46) ALDH1A1PKMBCHEMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3835290-A1 OXADIAZOLINE COMPOUND OR SALT THEREOF, AGRICULTURAL OR HORTICULTURAL BACTERICIDE CONTAINING SAID COMPOUND, AND USE METHOD THEREFOR Nihon Nohyaku Co., Ltd. (JP) 2021-06-16 EP disclosed
US-8476445-B2 Process for production of piperidine derivatives ALBANY MOLECULAR RESEARCH, INC. (US) 2013-07-02 US disclosed
US-20100137605-A1 PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES ALBANY MOLECULAR RESEARCH, INC. (US) 2010-06-03 US disclosed
US-7678915-B2 Process for production of piperidine derivatives ALBANY MOLECULAR RESEARCH, INC. (US) 2010-03-16 US disclosed
US-20070010677-A1 Process for production of piperidine derivatives AMR TECHNOLOGY, INC. (US) 2007-01-11 US disclosed
US-20050209279-A1 Process for production of piperidine derivatives AMR TECHNOLOGY, INC. (US) 2005-09-22 US disclosed
US-6919458-B2 Process for production of piperidine derivatives AMR TECHNOLOGY, INC. (US) 2005-07-19 US disclosed
EP-0868182-B1 PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES ALBANY MOLECULAR RES INC (US) 2003-09-03 EP disclosed
US-20030028029-A1 Process for production of piperidine derivatives BARCLAYS BANK PLC, AS THE COLLATERAL AGENT 2003-02-06 US disclosed
US-6458958-B1 PROCESS OF PREPARING A PIPERIDINE DERIVATIVE COMPOUND OF THE FORMULA: ACYLATING AN .ALPHA.,.ALPHA.-DISUBSTITUTED-METHYLBENZENE DERIVATIVE HAVING THE FORMULA: ALBANY MOLECULAR RESEARCH, INC. 2002-10-01 US disclosed
US-6444824-B1 ANTISEROTONINE AGENTS; SIDE EFFECT REDUCTION ALBANY MOLECULAR RESEARCH, INC. 2002-09-03 US disclosed
US-6153754-A Process for production of piperidine derivatives ALBANY MOLECULAR RESEARCH, INC. (US) 2000-11-28 US disclosed
EP-0868182-A4 PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES ALBANY MOLECULAR RES INC (US) 1999-04-07 EP disclosed
EP-0868182-A1 PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES ALBANY MOLECULAR RESEARCH, INC. (US) 1998-10-07 EP disclosed
WO-1997023213-A1 PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES ALBANY MOLECULAR RESEARCH, INC. (US) 1997-07-03 WO disclosed
WO-1997009983-A1 PIPERIDINE DERIVATIVES AND PROCESSES FOR THEIR PRODUCTION ALBANY MOLECULAR RESEARCH, INC. (US) 1997-03-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137605-A1 PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES HPD, PTMA, HAAO ALDH1A1 20/4885PKM 375/4885BCHE 691/4885
US-20050209279-A1 Process for production of piperidine derivatives NR5A2, NR4A1, NR4A2 ALDH1A1 1917/4885PKM 4793/4885BCHE 2822/4885
US-20070010677-A1 Process for production of piperidine derivatives NR4A1, NR5A2, NR4A2 ALDH1A1 1155/4885PKM 4530/4885BCHE 2900/4885
US-20030028029-A1 Process for production of piperidine derivatives NR4A1, RCOR1, CBR1 ALDH1A1 1129/4885PKM 4267/4885BCHE 2161/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.